Takeda, CSL Behring fold big plasma alliance after PhIII flop — joining a slew of antibodies that failed to help hospitalized patients
The big plasma alliance spearheaded by Takeda and CSL Behring has a big Phase III verdict: Adding their hyperimmune intravenous immunoglobulin product to Gilead’s remdesivir does not stall disease progression.
Dubbed H-Ig, the treatment was supposed to be a higher grade version of convalescent plasma, which former President Donald Trump once hailed as a “historic breakthrough.” But it seems to be following plasma down the same path toward obsolescence.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.